$LFCR News

Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5

Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company

Lifecore Biomedical (LFCR) Stock Draws Fresh Price Target Split After FY26 Outlook

Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer

Lifecore Biomedical Signs Manufacturing Services Agreement To Perform Process Development And Technical Transfer Services In Support Of Anticipated Commercial Manufacturing Upon Regulatory Approval

How The Lifecore Biomedical (LFCR) Narrative Is Shifting On Guidance, Timing And 2028 Expectations

Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference

Lifecore Biomedical to Participate at CDMO Live Europe

Lifecore Biomedical, Inc. (LFCR) Q1 2026 Earnings Call Transcript

Lifecore Biomedical, Inc. 2026 Q1 - Results - Earnings Call Presentation

Lifecore Biomedical Q1 Earnings Call Highlights

Lifecore Biomedical (NASDAQ:LFCR) Posts Q1 Revenue Miss and Wider-Than-Expected Loss

Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update

Lifecore Biomedical Q1 2026 Earnings Call Transcript

Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.430M Est

Lifecore Biomedical Q1 EPS $(0.43) Misses $(0.24) Estimate, Sales $23.193M Miss $26.501M Estimate

Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026

Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6

Laughing Water Capital’s Insights on Lifecore Biomedical (LFCR)

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)